Vir Biotechnology (VIR)
(Delayed Data from NSDQ)
$8.77 USD
+0.45 (5.41%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $8.76 -0.01 (-0.11%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Vir Biotechnology, Inc. (VIR) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$31.25 | $110.00 | $13.00 | 275.60% |
Price Target
Based on short-term price targets offered by eight analysts, the average price target for Vir Biotechnology, Inc. comes to $31.25. The forecasts range from a low of $13.00 to a high of $110.00. The average price target represents an increase of 275.6% from the last closing price of $8.32.
Analyst Price Targets (8 )
Broker Rating
Vir Biotechnology, Inc. currently has an average brokerage recommendation (ABR) of 1.78 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by nine brokerage firms. The current ABR compares to an ABR of 1.78 a month ago based on nine recommendations.
Of the nine recommendations deriving the current ABR, five are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 55.56% and 11.11% of all recommendations. A month ago, Strong Buy made up 55.56%, while Buy represented 11.11%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/VIR.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 5 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 3 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.78 | 1.78 | 1.78 | 1.78 | 1.78 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/20/2024 | H.C. Wainwright & Co. | Patrick Trucchio | Strong Buy | Strong Buy |
6/6/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/22/2024 | SVB Securities | Roanna Ruiz | Strong Buy | Strong Buy |
5/3/2024 | Needham & Company | Joseph R Stringer | Moderate Buy | Moderate Buy |
4/1/2024 | Cowen & Co. | Philip M Nadeau | Strong Buy | Strong Buy |
3/31/2024 | Goldman Sachs | Paul K Choi | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.78 |
ABR (Last week) | 1.78 |
# of Recs in ABR | 9 |
Average Target Price | $31.25 |
LT Growth Rate | 4.30% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 81 of 253 |
Current Quarter EPS Est: | -0.96 |